Production (Stage)
ReShape Lifesciences Inc.
RSLS
$4.76
-$0.18-3.64%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.81M | 2.29M | 1.97M | 1.94M | 1.98M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.81M | 2.29M | 1.97M | 1.94M | 1.98M |
| Cost of Revenue | 486.00K | 853.00K | 831.00K | 779.00K | 140.00K |
| Gross Profit | 1.32M | 1.44M | 1.13M | 1.17M | 1.84M |
| SG&A Expenses | 1.44M | 2.80M | 2.79M | 2.89M | 3.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.45M | 4.05M | 4.02M | 4.15M | 3.88M |
| Operating Income | -642.00K | -1.76M | -2.05M | -2.21M | -1.90M |
| Income Before Tax | -1.76M | -1.58M | -1.58M | -2.18M | -1.67M |
| Income Tax Expenses | 5.00K | 6.00K | 15.00K | 14.00K | 31.00K |
| Earnings from Continuing Operations | -1.76M | -1.58M | -1.60M | -2.19M | -1.70M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.76M | -1.58M | -1.60M | -2.19M | -1.70M |
| EBIT | -642.00K | -1.76M | -2.05M | -2.21M | -1.90M |
| EBITDA | -637.00K | -1.76M | -2.05M | -2.20M | -1.89M |
| EPS Basic | -61.71 | -77.68 | -91.69 | -135.56 | -159.92 |
| Normalized Basic EPS | -37.67 | -48.36 | -72.18 | -84.19 | -98.12 |
| EPS Diluted | -61.71 | -77.68 | -91.69 | -135.56 | -159.92 |
| Normalized Diluted EPS | -37.67 | -48.36 | -72.18 | -84.19 | -98.12 |
| Average Basic Shares Outstanding | 28.50K | 20.40K | 17.40K | 16.20K | 10.60K |
| Average Diluted Shares Outstanding | 28.50K | 20.40K | 17.40K | 16.20K | 10.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |